Evolution of breast cancer incidence in relation to hormone replacement therapy use in Belgium

Climacteric

Volumn 14, Issue 4, 2011, Pages 464-471

  Antoine, C ^a   Ameye, L ^b   Moreau, M ^b   Paesmans, M ^b   Rozenberg, S ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Belgium; Breast cancer; Hormone replacement therapy; Incidence

Indexed keywords

CONJUGATED ESTROGEN; DROSPIRENONE; DYDROGESTERONE; ESTRADIOL; ESTROGEN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE; NORETHISTERONE; NORGESTREL; PROGESTERONE; SEX HORMONE; TIBOLONE;

ADULT; AGED; ARTICLE; BELGIUM; BODY WEIGHT; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; EVOLUTION; FEMALE; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; BELGIUM; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; PROGESTINS; RISK FACTORS;

EID: 79960445310     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2011.561385     Document Type: Article

References (33)

1. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA 1999; 281: 2091-7
2. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-32 (Pubitemid 30117736)
3. Weiss LK, Burkman RT, Cushing-Haugen KL, et al. Hormone replacement therapy regimens and breast cancer risk (1). Obstet Gynecol 2002;100:1148-58 (Pubitemid 35449180)
4. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33 (Pubitemid 34761611)
5. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-57
6. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27 (Pubitemid 36999703)
7. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-11 (Pubitemid 350179584)
8. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-4 (Pubitemid 46631679)
9. Canfell K, Banks E, Moa AM, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 2008;188:641-4
10. Bouchardy C, Usel M, Verkooijen HM, et al. Changing pattern of age-specific breast cancer incidence in the Swiss canton of Geneva. Breast Cancer Res Treat 2010;120:519-23
11. Katalinic A, Lemmer A, Zawinell A, Rawal R, Waldmann A. Trends in hormone therapy and breast cancer incidence-results from the German Network of Cancer Registries. Pathobiology 2009;76:90-7
12. Séradour B, Allemand H, Weill A, Ricordeau P. Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. Bull Cancer 2009;96:E1-6
13. Soerjomataram I, Coebergh JW, Louwman MW, Visser O, van Leeuwen FE. Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands? J Clin Oncol 2007;25:5038-9 (Pubitemid 350220443)
14. Verkooijen HM, Koot VC, Fioretta G, et al. Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations. Breast Cancer Res Treat 2008;107:389-95 (Pubitemid 351172106)
15. Lundberg V, Tolonen H, Stegmayr B, Kuulasmaa K, Asplund K; WHO MONICA Project. Use of oral contraceptives and hormone replacement therapy in the WHO MONICA project. Maturitas 2004;48:39-49 (Pubitemid 38829105)
16. Parkin DM. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer 2009;45:1649-53
17. Robbins AS, Clarke CA. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 2007;25:3437-9 (Pubitemid 47310880)
18. Hemminki E, Kyyrönen P, Pukkala E. Postmenopausal hormone drugs and breast and colon cancer: Nordic countries 1995-2005. Maturitas 2008;61:299-304
19. Kumle M. Declining breast cancer incidence and decreased HRT use. Lancet 2008;372:608-10
20. Prentice RL, Huang Y, Hinds DA, et al. Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2009;18:3079-85
21. Rebbeck TR, DeMichele A, Tran TV, et al. Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis 2009;30:269-74
22. Ena G, Rozenberg S. Issues to debate on the Women's Health Initiative (WHI) study. Prescription attitudes among Belgian gynaecologists after premature discontinuation of the WHI study. Hum Reprod 2003;18:2245-8 (Pubitemid 37427798)
23. Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 2004;328:921-4 (Pubitemid 38496981)
24. Verkooijen HM, Bouchardy C, Vinh-Hung V, Rapiti E, Hartman M. The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence. Maturitas 2009;64:80-5
25. Gompel A, Plu-Bureau G. Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy? Ann N Y Acad Sci 2010;1205:268-76
26. Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007;99:1152-61 (Pubitemid 47233065)
27. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007;9:R28
28. Kliewer EV, Demers AA, Nugent ZJ. A decline in breast-cancer incidence. N Engl J Med 2007;357:509-10
29. Li CI, Daling JR. Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 2007;16: 2773-80 (Pubitemid 351196336)
30. Renard F, Vankrunkelsven P, Van Eycken L, Henau K, Boniol M, Autier P. Decline in breast cancer incidence in the Flemish region of Belgium after a decline in hormonal replacement therapy. Ann Oncol 2010;21:2356-60
31. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360:573-87
32. Vankrunkelsven P, Kellen E, Lousbergh D, et al. Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat 2009;118:425-32
33. Lambe M, Wigertz A, Holmqvist M, et al. Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years. Breast Cancer Res Treat 2010;121:679-83